Intermittent Intravenous Insulin Therapy

Aetna considers intermittent intravenous insulin therapy (including hepatic/metabolic activation, pulse/pulsatile IV insulin, Trina Health artificial pancreas), insulin potentiation therapy, and related glucose/potassium/respiratory quotient/urine urea nitrogen testing experimental/investigational and not covered. These approaches are excluded because their clinical effectiveness has not been established; the policy does not apply to standard continuous insulin infusions for DKA/HHS.

"Aetna considers the following procedures experimental and investigational because the effectiveness of these approaches has not been established:"

Sign up to see full coverage criteria, indications, and limitations.